JMP maintains Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities LLC analyst Adam Cutler at a market outperform rating with a $3 price target as weekly prescription volumes for Factive and Testim were tracked by JMP. Factive prescriptions for respiratory infections represented 0.65% of the prescriptions for the week ended Oct. 14 in the quinolone class of antibiotics, compared with 0.66% for the previous week. Scripts for Testim, a testosterone gel product co-promoted with Auxillium, were 4,626 for the week ended Oct. 14 versus 4,509 scripts for the previous week. Shares of the Waltham, Mass.-based pharmaceutical company were up $0.16, or 8.99%, at $1.94 on volume of 521,556 shares versus the three-month running average 766,030 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.